Influence of Preparation Methods on Physicochemical and Pharmacokinetic Properties of Co-amorphous Formulations: The Case of Co-amorphous Atorvastatin: Naringin

被引:32
|
作者
Nair, Athira [1 ]
Varma, Raghava [1 ]
Gourishetti, Karthik [2 ]
Bhat, Krishnamurthy [1 ]
Dengale, Swapnil [1 ]
机构
[1] Manipal Acad Higher Educ, Manipal Coll Pharmaceut Sci, Dept Pharmaceut Qual Assurance, Manipal 576104, Karnataka, India
[2] Manipal Acad Higher Educ, Manipal Coll Pharmaceut Sci, Dept Pharmacol, Manipal 576104, India
关键词
Co-amorphous; Atorvastatin; Naringin; Ball milling; Solvent evaporation; Quench cooling; SOLID-STATE CHARACTERIZATION; IMPROVED PHYSICAL STABILITY; WATER-SOLUBLE DRUGS; DISSOLUTION RATE; COAMORPHOUS ATORVASTATIN; ENHANCED BIOAVAILABILITY; ENTHALPIC RELAXATION; BINARY-SYSTEMS; DOSAGE FORMS; AMINO-ACIDS;
D O I
10.1007/s12247-019-09381-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose The goal of the study was to investigate the influence of processing methods on the physicochemical and pharmacokinetic properties of co-amorphous materials. Methods Co-amorphous formulations of atorvastatin (ATV) and naringin (NRG) in the molar ratio 1:1 were prepared by quench cooling (ANQC), solvent evaporation (ANSE), and ball milling (ANBM) and characterized by differential scanning calorimetry (DSC), powder X-ray diffractometry (XRPD), and Fourier transform infrared spectroscopy (FTIR). Further, the performance of prepared co-amorphous formulations was evaluated in vitro and in vivo. Results All processing methods yielded homogeneous co-amorphous formulation, which was confirmed by single glass transition (Tg) event and diffuse halo in DSC and XRPD, respectively. Irrespective of processing method employed, all co-amorphous formulations were found stable at 30 degrees C for 90 days in dry conditions (under vacuum). Significant improvement in the solubility of ATV was observed in ANQC and ANSE co-amorphous formulations, highest being 56-fold for the later. ATV from ANSE formulation showed highest drug release (97%), while surprisingly ANQC showed significantly lower ATV release as compared to the physical mixture. Amongst three preparation methods, solubility advantage of ANSE could translate into efficacious pharmacokinetic parameters, where the improvement in ATV exposure (AUC 0-t) and plasma concentration (Cmax) were found 4.5-fold and 7-fold, respectively, as compared to the physical mixture. Conclusion It was concluded that the preparation methods of co-amorphous formulations have a profound effect on physical properties like stability, physicochemical properties like solubility, dissolution rate, and pharmacokinetic properties like AUC and Cmax.
引用
收藏
页码:365 / 379
页数:15
相关论文
共 50 条
  • [31] Co-former selection for co-amorphous drug-amino acid formulations
    Kasten, Georgia
    Lobmann, Korbinian
    Grohganz, Holger
    Rades, Thomas
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2019, 557 : 366 - 373
  • [32] Improvement of the physicochemical properties of Co-amorphous naproxen-indomethacin by naproxen-sodium
    Beyer, Andreas
    Grohganz, Holger
    Lobmann, Korbinian
    Rades, Thomas
    Leopold, Claudia S.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2017, 526 (1-2) : 88 - 94
  • [33] The relevance of co-amorphous formulations to develop supersaturated dosage forms: In-vitro, and ex-vivo investigation of Ritonavir-Lopinavir co-amorphous materials
    Anand, V. Sai Krishna
    Sakhare, Sujata D.
    Sree, Navya K. S.
    Nair, Athira R.
    Varma, K. Raghava
    Gourishetti, Karthik
    Dengale, Swapnil J.
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 123 : 124 - 134
  • [34] Downstream Processing of Amorphous and Co-Amorphous Olanzapine Powder Blends
    da Costa, Nuno F.
    Daniels, Rolf
    Fernandes, Ana I.
    Pinto, Joao F.
    PHARMACEUTICS, 2022, 14 (08)
  • [35] Design and molecular insights of drug-active metabolite based co-amorphous formulation: A case study of toltrazuril-ponazuril co-amorphous
    Li, Bin
    Wang, Yingyun
    Feng, Ying
    Yuan, Dan
    Xu, Renjie
    Jiang, Cuiping
    Xiao, Xuecheng
    Lu, Shan
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2022, 615
  • [36] CO-AMORPHOUS DRUG COMBINATIONS FOR INHALATION THERAPY
    Dieplinger, Johanna
    Mitsche, Stefan
    Schroettner, Hartmuth
    Neugebauer, Sarah
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2023, 36 (06) : A11 - A11
  • [37] Measurement of the amorphous fraction of olanzapine incorporated in a co-amorphous formulation
    Costa, Nuno F.
    Fernandes, Ana, I
    Pinto, Joao F.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2020, 588
  • [38] Wet granulation of co-amorphous indomethacin systems
    Schutz, David
    Timmerhaus, Annika
    Grohganz, Holger
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2023, 644
  • [39] Design of experiments approach on the compaction properties of co-amorphous tablets
    Engelsing, Florian
    Buchart, Laura
    Grohganz, Holger
    PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2023, 28 (09) : 907 - 914
  • [40] Intelligent Mechanochemical Design of Co-Amorphous Mixtures
    Grols, Jan R.
    Castro-Dominguez, Bernardo
    CRYSTAL GROWTH & DESIGN, 2022, 22 (05) : 2989 - 2996